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includes isolation of lymphocytes from the whole white blood cell mass via density-gradient centrifugation; followed by stimulation using either tumor-antigen pulsed dendritic cells, either with a combination of IFN-γ + anti-CD3 mAb (often additional mAbs, commonly anti-CD28); followed by culture and expansion in growth medium with added cytokines (usually IL-2 and other) [1, 3-5, 11-13, 22, 24-25, 27-28] .
During the recent few years, advanced approaches, which involve the transfection of CIKs with genetically-engineered tumor-antigen-specific natural or chimeric TCRs, are also rapidly emerging and ongoing multiple successful clinical trials [3-5, 11-12, 18, 25] . Also, ACT can be combined with such treatments as administration of "immune checkpoint" blocking monoclonal antibodies [9] , bispecific antibodies [2] [3] [4] and other approaches, which have been shown to increase ACT efficacy. Numerous ACT strategies which use CIK have been already approved for clinical use in many countries (e.g. USA, China, countries of European Union, etc.), and significant therapeutic success has been achieved in many cases. Depending on clinical protocol and on properties of specific tumor (for instance, melanomas [11, 16, 17, 26] and lung cancers [11] are often highly immunogenic, thus CIK therapy works particularly well against them), range of ~30% to ~80% of partial and even complete clinical response rates has been achieved [ Previously, at early stages of development of ACT cancer immunotherapy, it was considered, that CD4 + T helpers play the major role in antitumor response within CIK/TIL mixture. For instance Steven Rosenberg, one of big gurus in immunotherapy, has shared this view for many years [18, 29, 30] .
However, Rosenberg himself, along with another researchers, acknowledges, that only a limited clinical success of geneticallyunmodified T-helper-focused adoptive transfer therapy has been achieved so far [7, [25] [26] .
So it looks like, that benefit of CD4 + T helpers -based approach for ACT is a big issue.
PROBLEMS ASSOCIATED WITH ALL CD3 + TCR + T CELLS
First, extensively-cultured, antigen-exposure exhausted, highlydifferentiated T cell lines are prone to senescence and apoptosis, and therefore have a short survival time after infusion to a patient's body [17] [18] [25] [26] .
Second, TCR high specificity leads to a fact that only a very limited percentage of T cell clones are reactive to specific tumor antigens. This issue can be partly overcome (apart from genetic modification) by pulsing of bulk CIK culture with a tumor lysate or particular tumor marker antigen, followed by selection of useful, i.e. Ag-reactive clones with the help of cytotoxicity-or cytokine-secretion assays and choosing them for further culture and expansion [30] .
Third, majority of tumor antigens (apart from oncogenic-virus Ags and neo-Ags which bear a mutation) are self-Ags; although expressed either ectopically, either at abnormally-high levels, either at a wrong developmental stage. It makes them weakly-immunogenic [11, 33] , and immune response to them is tightly controlled by natural and induced T regulatory lymphocytes, which will be discussed in the section below.
Fourth, tumor-Ag-specific T cells are highly prone to be "turned off" by ligands to so-called "immune-checkpoint" receptors [9] , or incited to undergo apoptosis by proapoptotic ligands (e.g. FasL etc.), which have been shown to be highly expressed on many tumors [7] .
CD4 + T HELPERS: EVEN MORE PROBLEMS
And moreover, in addition to the above-listed limitations of T-cellfocused immunotherapy, CD4 + T-helpers seem to be the "trickiest" subset of effector T lymphocytes. CD4 + T helpers take part in amplifying immune response via secreting immune-boosting cytokines such as IL-2, IFN-γ etc.; and by "triggering on" B cells and CD8 + cytotoxic lymphocytes [2, 30] . However, there are reports, stating that T-helpers contribute only to a very limited extent to antitumor action of CIK [16, 32] . The main point of T helpers is regulation of immune response, boosting it or quenching it when necessary or, in pathology, when being disregulated (e.g. in cancer) -when unnecessary. By the way, it has been stated previously, that Th1 cells are more susceptible to suppression and/or anergy than CD8 + cells [34] . Th1/Th2 differentiation also may be involved: Th2 subset has been shown to have immune-modulatory and even cell-immunity-suppressive properties by many researchers [6, 10, 35- Conclusions of Shevach E. [37] are also consistent with this -according to the author of this review about Tregs mechanism of action, Th1 cells under certain conditions can definitely exert immunosuppressive properties via secreting immunohibitory cytokines, such as IL-10 and TGF-β [37] . The reasons and mechanisms how and why CD4 + T helpers can acquire immunosuppressive properties, are discussed in the section below. Few direct citations from two good review articles will be appropriate here:
TUMOR IMMUNE ESCAPE: INDUCTION AND RECRUITMENT OF TREGS AS ONE OF ITS MAJOR MECHANISMS. INFECTIOUS TOLERANCE
"Constitutive presentation of self-antigens by immature dendritic cells; high levels of transforming growth factor-β and prostaglandin E2 (derived in part from elevated COX-2 expression) in the tumor microenvironment may also enhance the conversion of FoxP3-negative CD4 + T-cell effectors to FoxP3-positive regulatory T cells. In transplantable tumor models, the administration of antibodies to CD4 or CD25, which effectively antagonize regulatory T-cell function, established a critical role for regulatory T cellmediated immune suppression at both early and late stages of disease, as these manipulations evoked impressive tumor regressions and protection against subsequent tumor challenges" [8] .
" 
CD25
+ FoxP3 + Tregs. Many tumors either directly secrete TGF-β and IL-10, along with other immune-suppressive molecules, either incite non-transformed cells (such as TIM/TAM -tumor-infiltrating/ associated macrophages) and myeloid-derived suppressor cells in tumor microenvironment to do so [9, 18, [32] [33] [34] 49] .
By the way, targeting of T regulatory lymphocytes in cancer patient's body (either through depletion, either through inactivation, either through disrupting the mechanisms of Tregs recruitment by tumor) is one of promising directions in cancer immunotherapy [33, 47, 52] , which can have huge synergistic positive effect when combined with CIK ACT approach.
Moreover, some FoxP3-negative suppressor T-lymphocyte populations Tr1 and Th3 can be induced from CD4 + CD25 -T effectors [10] This is also the case with other immune-inhibitory molecules (e.g. CTLA-4, CD25, OX40/CD137), which are constitutely expressed on Tregs, and transiently -on recently activated T effector cells, largely on CD4 + T helpers [10, 37, 39-40, 47, 49-50] .
CLINICAL RESULTS
High level of CD4
+ cells (up to 85%) in transfected bulk lymphocyte culture might be the cause of absence of any therapeutic success in several clinical trials with the use of anti-cancer chimeric antigen receptor (CAR) transduced T cells; whereas in those trials where transfected cultures contained relatively low (~45%) CD4 + T cells ratio, significant therapeutic success has been achieved [3] .
In a number of highly-successful clinical trials with CAR-or natural antigen-specific αβ-TCR-transfected T cells, the majority of tumorinfiltrating, malignancy-attacking players (as the analysis of posttreatment biopsies has indicated) were not CD4 + , but CD8 + αβ-TCR/CAR transfected cells [4] [5] 11] .
POSSIBLE SOLUTIONS
Taken together all the above-said, there's no surprise, that some therapeutic centers, which perform ACT, nowadays deplete CD4 + cells (mostly using MACS (magnetic-associated cell sorting)) from full-grown clinical grade CIK cultures, in order to obtain CD8 + CTL-enriched CIK population [12] .
The less radical approach would be the depletion or inactivation of CD4
+ Tregs from expanded clinical bulk CIK cultures, which is most practically achieved by using MACS -a procedure which has been proposed by number of researchers [2, 14] . Designing of culture protocols that disfavor Tregs proliferation (e.g., addition of IL-7 and IL-15 to cytokine mixture) can also be an option [13] . These measures would prevent cascade-like generation of large quantity of CD4 + iTregs from CD4 + T helpers caused by "infectious tolerance" in vitro; but it would probably fail to do so in vivo, i.e within a patient's body, in a tumor immunosuppressive microenvironment.
Another direct citation will be to place here: "Tumour-induced expansion of regulatory T (Treg) cells is an obstacle to successful cancer immunotherapy. In theory, the functional inactivation of Treg cells will maintain them at high numbers in tumours and avoid their replenishment from the peripheral lymphocyte pool, which has the capacity to further suppress the effector lymphocyte anti-tumour response" [49] . 
SUMMARY
